Oric Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company that sets new benchmarks in the world of cancer treatment. Established in 2014, and based in South San Francisco, California, the company is esteemed for its dedication to overcoming treatment resistance in cancer patients.
Oric Pharmaceuticals upholds a mission to "discovery the undiscovered," which involves extensively researching and developing novel treatments that can strategically counteract the mechanisms by which cancers fight back against treatment. They believe that by discovering these resistance mechanisms, they can create therapies that limit the effectiveness of tumors and overcome resistance to see effective results in treating cancer.
The company has an impressive pipeline of product candidates. Its leading candidate is ORIC-101, which demonstrates important functions in multiple resistance mechanisms to various cancer therapies. This small molecule glucocorticoid receptor antagonist is being developed for solid tumors resistant to checkpoint inhibition and metastatic prostate cancer. Beyond ORIC-101, there are also three other drugs at different stages of development set to cater to different types of cancer.
ORIC's research, backed by high scientific rigor, targets the significant needs of patients who do not respond, or no longer respond to current cancer therapies. Their staff consists of scientific pioneers and experienced drug developers who continue to augment the company's drug pipeline.
In addition to its leading innovations in cancer treatment, ORIC is also known for its strong collaborations with noted biotech and pharma companies. Over the years, the company has managed to secure persistent funding from leading venture capital firms, industry partners, public investors and non-profit partners.
Interestingly, the term ORIC stands for 'Overcoming Resistance In Cancer,' reflecting the company's relentless determination and commitment to fight cancer. This also underscores the company's ethos in continuously seeking ways to outsmart cancer and its adaptability to resist treatment. They expose the cancer's playbook, target treatment, and help more people overcome the disease.
Oric Pharmaceuticals went public in April 2020, joining the NASDAQ under the ticker symbol "ORIC." Despite the challenges of the Covid-19 pandemic, the company has continued to make incredible strides in its quest to bring novel, effective cancer treatments to patients. Its relentless pursuit of pioneering techniques to overcome resistance distinguishes ORIC Pharmaceuticals, Inc. as a beacon of hope in the cancer treatment landscape.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article provides a liquidity mapping analysis for Oric Pharmaceuticals Inc. (NASDAQ: ORIC), noting weak near-term and mid-term sentiment, despite a positive long-term outlook. It identifies key support and resistance signals and outlines three AI-generated institutional trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, each with specific entry, target, and stop-loss zones.
Stifel's Laura Prendergast maintained a "Buy" rating for ORIC Pharmaceuticals (ORIC) and raised its price target to $18.00 from $14.00, an increase of 28.57%. This positive outlook reflects optimism about ORIC's growth potential in the biotechnology sector, despite the company being unprofitable and cash-flow-negative, with a GF Score™ of 40/100 indicating mixed financial performance. Insider activity shows significant selling, which could be a concern for investors.
Oric Pharmaceuticals (NASDAQ:ORIC) stock recently fell below its 200-day moving average, trading at $8.95 after hitting a low of $8.88, with a significant volume of 6.9 million shares. Despite this decline, analysts largely maintain a "Moderate Buy" rating with an average price target of $21.50, driven by numerous "Buy" recommendations. While institutional ownership is high, company insiders have sold over 105,000 shares worth $1.43 million in the last 90 days.
Wedbush has lowered its price target for ORIC Pharmaceuticals (ORIC) from $17 to $14 but has maintained its "Outperform" rating on the stock. The article indicates that ORIC Pharmaceuticals has an average "buy" rating among analysts with a mean price target of $21.71. Access to the full details of this report requires a premium subscription.